• Magdalene M Assimon, Shaker Mousa, Olfat Shaker, and Amy Barton Pai.
• Albany College of Pharmacy and Health Sciences, Albany, New York 12208, USA.
• Consult Pharm. 2010 Jan 1; 25 (1): 41-54.

ObjectiveTo review phosphate-binder choice and mortality in hemodialysis patients.Data SourcesA literature search was performed using the PUBMED database to identify clinical trials published from January 1966 through January 2009. Search terms included: sevelamer and mortality, calcium acetate and mortality, and calcium carbonate and mortality.Study SelectionClinical trials relating the effect of phosphate-binder choice on cardiovascular disease and mortality in hemodialysis patients, judged to be pertinent by the authors, were selected for discussion. DATA SYNTHESIS/CONCLUSIONS: The Renagel in New Dialysis (RIND) extension study and the Dialysis Clinical Outcomes Revisted (DCOR) study were the first clinical trials to compare the effects of calcium-based phosphate binders and sevelamer hydrochloride on mortality in hemodialysis patients. Based on the results of these and other studies evaluated, it is still unclear if sevelamer hydrochloride has a survival benefit in hemodialysis patients over calcium-based phosphate binders.

24 keywords...

hide…